REGENXBIO (RGNX) vs Tectonic Therapeutic (TECX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tectonic Therapeutic (TECX) has outperformed REGENXBIO (RGNX) over the past year, gaining 52.3% versus a loss of 27.7%. Over five years, TECX leads with a -67.4% price change compared with -78.9% for RGNX. REGENXBIO is the larger company by market cap ($514.6 million vs $430.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RGNX | TECX |
|---|---|---|
| Share price | $7.80 | $22.01 |
| Market cap | $514.57M | $430.18M |
| 1-day change | +2.63% | -3.11% |
| YTD return | -47.26% | +8.87% |
| 1-year return | -27.74% | +52.31% |
| 5-year return | -78.87% | -67.37% |
| EPS (TTM) | $-3.78 | $-4.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.19 | $39.53 |
| 52-week low | $5.46 | $15.32 |
| Distance from 52-week high | -51.85% | -44.33% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +202.50% | +248.24% |
| Average volume | 1.52M | 220.39K |
| Shares outstanding | 66.01M | 19.55M |
| Employees | 371 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TECX has outperformed RGNX by 80.0 percentage points over the past year.
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
About Tectonic Therapeutic
TECX stock →Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
RGNX vs TECX FAQ
Which is bigger, REGENXBIO or Tectonic Therapeutic?
REGENXBIO (RGNX) is larger, with a market capitalization of $514.57M compared with $430.18M for Tectonic Therapeutic (TECX).
Which stock has performed better over the past year, RGNX or TECX?
TECX returned +52.31% over the past 12 months, compared with -27.74% for RGNX (price return, excluding dividends). Past performance does not predict future results.
Are REGENXBIO and Tectonic Therapeutic in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.